Tyrosine Kinase Inhibitors in Clinical Practice: Patient Selection

European Urology, Supplements

Volumn 7, Issue 9, 2008, Pages 601-609

  Patard, Jean Jacques ^a  

^a PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

Author keywords

Renal cell carcinoma; Sunitinib; Treatment algorithm; Tyrosine kinase inhibitor

Indexed keywords

ALPHA INTERFERON; AXITINIB; BEVACIZUMAB; CYTOKINE; EVEROLIMUS; INTERLEUKIN 2; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PAZOPANIB; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; TEMSIROLIMUS;

CANCER LOCALIZATION; CANCER SURVIVAL; CLINICAL PRACTICE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; HUMAN; KIDNEY CARCINOMA; METASTASIS; MONOTHERAPY; PATIENT SELECTION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK FACTOR; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

EID: 49149110825     PISSN: 15699056     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eursup.2008.06.001     Document Type: Review

References (42)

1. Motzer R.J., Rini B.I., Bukowski R.M., et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295 (2006) 2516-2524
2. Motzer R.J., Mazumdar M., Bacik J., et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 17 (1999) 2530-2540
3. Motzer R.J., Bacik J., Murphy B.A., Russo P., and Mazumdar M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 20 (2002) 289-296
4. Motzer R.J., Figlin R.A., Hutson T.E., et al. Sunitinib versus interferon-alfa (IFNα) as first-line treatment of metastatic renal cell carcinoma (mRCC):updated results and analysis of prognostic factors. J Clin Oncol 25 (2007) 240S
5. Motzer R.J., Bacik J., Schwartz L.H., et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 22 (2004) 454-463
6. Choueiri T.K., Garcia J.A., Elson P., et al. Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. Cancer 110 (2007) 543-550
7. Gore M., Szczylik C., Porta C., et al. Sunitinib in metastatic renal cell carcinoma (mRCC): preliminary assessment of safety and efficacy in an expanded access trial with subpopulation analysis [abstract]. Eur J Cancer Suppl 5 (2007) 299
8. Motzer R.J., Michaelson M.D., and Hutson T.E. Sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC): updated efficacy and safety results and further analysis of prognostic factors [abstract]. Eur J Cancer Suppl 5 (2007) 301
9. Motzer R.J., Bander N.H., and Nanus D.M. Renal-cell carcinoma. N Engl J Med 335 (1996) 865-875
10. Cheville J.C., Lohse C.M., Zincke H., Weaver A.L., and Blute M.L. Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am J Surg Pathol 27 (2003) 612-624
11. Gudbjartsson T., Hardarson S., Petursdottir V., Thoroddsen A., Magnusson J., and Einarsson G.V. Histological subtyping and nuclear grading of renal cell carcinoma and their implications for survival: a retrospective nation-wide study of 629 patients. Eur Urol 48 (2005) 593-600
12. Upton M.P., Parker R.A., Youmans A., McDermott D.F., and Atkins M.B. Histologic predictors of renal cell carcinoma response to interleukin-2-based therapy. J Immunother 28 (2005) 488-495
13. Mekhail T.M., bou-Jawde R.M., Boumerhi G., et al. Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol 23 (2005) 832-841
14. Motzer R.J., Hutson T.E., Tomczak P., et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356 (2007) 115-124
15. Motzer RJ, Figlin R, Hutson TE, et al. Sunitinib versus interferon-alfa (IFNα) as first-line treatment of metastatic renal cell carcinoma (mRCC): updated results and analysis of prognostic factors. Oral presentation at: Annual Meeting of the American Society of Clinical Oncology; June 1-5, 2007; Chicago, IL, USA. Abstract 5024.
16. Motzer R.J., Michaelson M.D., Redman B.G., et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24 (2006) 16-24
17. George D.J., Michaelson M.D., Rosenberg J.E., et al. Sunitinib in patients with cytokine-refractory metastatic renal cell carcinoma (mRCC) [abstract]. Eur J Cancer Suppl 5 (2007) 303
18. Bellmunt J. Sunitinib in advanced renal cell carcinoma: clinical evidence. Eur Urol Suppl 7 (2008) 585-592
19. Ljungberg B., Hanbury D., and Kuczyk M. Renal cell carcinoma guideline. Eur Urol 51 (2007) 1502-1510
20. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: kidney cancer v.1.2008. Available at: http://www.nccn.org/professionals/physician_gls/PDF/kidney.pdf.
21. Escudier B., Pluzanska A., Koralewski P., et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370 (2007) 2103-2111
22. Rini BI, Halabi S, Rosenberg JE, et al. CALGB 90206: a phase III trial of bevacizumab plus interferon-alfa versus interferon-alfa monotherapy in metastatic renal cell carcinoma. Oral presentation at: 2008 Genitourinary Cancers Symposium of the American Society of Clinical Oncology; February 14-16, 2008; San Francisco, CA, USA. Abstract 350.
23. Hudes G., Carducci M., Tomczak P., et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356 (2007) 2271-2281
24. Dutcher J.P., Szczylik C., Tannir N., et al. Correlation of survival with tumor histology, age, and prognostic risk group for previously untreated patients with advanced renal cell carcinoma (adv RCC) receiving temsirolimus (TEMSR) or interferon-alpha (IFN) [abstract]. J Clin Oncol 25 Suppl (2007) 5033
25. Fyfe G., Fisher R.I., Rosenberg S.A., et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 13 (1995) 688-696
26. McDermott D.F., Regan M.M., Clark J.I., et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 23 (2005) 133-141
27. Yang J.C., Sherry R.M., Steinberg S.M., et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 21 (2003) 3127-3132
28. Szczylik C., Demkow T., Staehler M., Rolland F., and Negrier S. Randomized phase II trial of first line treatment with sorafenib versus interferon in patients with advanced renal cell carcinoma: final results [abstract]. J Clin Oncol 25 Suppl (2007) 5025
29. Rixe O., Bukowski R.M., Michaelson M.D., et al. Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. Lancet Oncol 8 (2007) 975-984
30. Rini B., Wilding G., Hudes G., et al. Axitinib (AG013736; AG) in patients with metastatic clear cell renal cell cancer (RCC) refractory to sorafenib [abstract]. Eur J Cancer Suppl 5 (2007) 300
31. Jac J., Giessinger S., Khan M., et al. A phase II trial of RAD001 in patients (Pts) with metastatic renal cell carcinoma (MRCC) [abstract]. J Clin Oncol 25 Suppl (2007) 5107
32. Amato R., Misellati A., Khan M., and Chiang S. A phase II trial of RAD001 in patients (Pts) with metastatic renal cell carcinoma (MRCC). J Clin Oncol 24 (2006) 4530
33. Hutson T.E., Davis I.D., Machiels J.P., et al. Pazopanib (GW786034) is active in metastatic renal cell carcinoma (RCC): interim results of a phase II randomized discontinuation trial (RDT) [abstract]. J Clin Oncol 25 Suppl (2007) 5031
34. Stadler W., and Figlin R. The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access trial: safety and efficacy in patients (pts) with non-clear cell (NCC) renal cell carcinoma (RCC) [abstract]. J Clin Oncol 25 Suppl (2007) 5036
35. Henderson C.A., Bukowski R.M., Stadler W.M., et al. Sorafenib therapy in the management of advanced renal cell carcinoma with brain metastases: results from the ARCCS expanded access program. Eur Urol Suppl 7 (2008) 245
36. Rini B.I., Jaeger E., Weinberg V., et al. Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: impact of patient characteristics and Von Hippel-Lindau gene status. BJU Int 98 (2006) 756-762
37. Choueiri T.K., Vaziri S.A., Rini P., et al. Use of Von-Hippel Lindau (VHL) mutation status to predict objective response to vascular endothelial growth factor (VEGF)-targeted therapy in metastatic renal cell carcinoma (RCC) [abstract]. J Clin Oncol 25 Suppl (2007) 5012
38. Atzpodien J., Schmitt E., Gertenbach U., et al. Adjuvant treatment with interleukin-2- and interferon-alpha2a-based chemoimmunotherapy in renal cell carcinoma post tumour nephrectomy: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). Br J Cancer 92 (2005) 843-846
39. Clark J.I., Atkins M.B., Urba W.J., et al. Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working gr*oup randomized trial. J Clin Oncol 21 (2003) 3133-3140
40. Jocham D., Richter A., Hoffmann L., et al. Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial. Lancet 363 (2004) 594-599
41. Eisen T. Adjuvant therapy in renal cell carcinoma: Where are we?. Eur Urol Suppl 6 (2007) 492-498
42. US National Institutes of Health. Clinical trials database. Available at: www.clinicaltrials.gov.